UPDATE: Vessix in hand, Boston Scientific targets Medtronic in high blood pressure market

November 8, 2012 by MassDevice staff

Boston Scientific executives tell MassDevice.com that the medical device company is aiming to have the 2nd renal denervation high blood pressure device on the U.S. market, behind arch-rival Medtronic, now that it's agreed to pay up to $425 million for Vessix Vascular.

Boston Scientific acquires Vessix

Get the complete picture with a MassDevice Plus membership. Registered users can login here.